Patent: 9,181,552
✉ Email this page to a colleague
Summary for Patent: 9,181,552
| Title: | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| Abstract: | Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies. |
| Inventor(s): | Lorenzi; Philip L. (Washington, DC), Weinstein; John N. (Chevy Chase, MD), Caplen; Natasha J. (Silver Spring, MD) |
| Assignee: | The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) |
| Application Number: | 13/151,420 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,181,552
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2026-03-03 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
